Equimed Pharma Bridge is AI Enabled Platform for accelerating entry of your idea

Insights

FDA Updates

Regulatory announcements & guidance

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

IP & Exclusivity Updates

Patents, Orange Book & market protection

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

NDA & ANDA Approvals

New drug and generic approvals

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

BLAs & Biosimilars

Biologics and biosimilar pathways

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Direct-to-Consumer Drug Program: New OIG Safeguards for Federal Program Enrollees
ACI’s Advanced Summit on Food Law Regulation, Compliance, and Litigation
FDA Signals Flexibility with Recent Single-Arm Approvals
ACI’s 44th Annual FDA Boot Camp
SCOTUS to Hear Skinny Label Dispute

Partners

Who We Serve